Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 322-328

  Apellániz Ruiz, María ^a   Lee, Mi Young ^b   Sánchez Barroso, Lara ^a   Gutiérrez Gutiérrez, Gerardo ^c   Calvo, Isabel ^d,e   García Estévez, Laura ^d   Sereno, María ^c   García Donás, Jesús ^f   Castelo, Beatriz ^g   Guerra, Eva ^h   Leandro García, Luis J ^a   Cascón, Alberto ^a,i   Johansson, Inger ^b   Robledo, Mercedes ^a,i   Ingelman Sundberg, Magnus ^b   Rodríguez Antona, Cristina ^a,i  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d Montepríncipe University Hospital   (Spain)

^e Centro Integral Oncologico Clara Campal   (Spain)

^f Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AGED; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYP3A4 GENE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; ONCOGENE; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; QUALITY OF LIFE; STOP CODON; WHOLE EXOME SEQUENCING; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CHEMICALLY INDUCED; DNA SEQUENCE; ENZYME STABILITY; EXOME; GENETICS; HEK293 CELL LINE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP3A; ENZYME STABILITY; EXOME; FEMALE; HEK293 CELLS; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SEQUENCE ANALYSIS, DNA;

EID: 84921033105     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1758     Document Type: Conference Paper

References (37)

1. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42:24-30.
2. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218-28.
3. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767-74.
4. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-42.
5. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-109.
6. Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 2013;50:599-605.
7. Rodriguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010;11:621-3.
8. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, et al. CYP3A4-22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013;19:3316-24.
9. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, et al. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.Clin Cancer Res 2005;11:4843-50.
10. Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011;11:121-9.
11. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, et al. CYP2C8-3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 2013;24:1472-8.
12. Biesecker LG. Exome sequencing makes medical genomics a reality. Nat Genet 2010;42:13-4.
13. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010;11: 415-25.
14. Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000;410:107-20.
15. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.
16. Gurwitz D, McLeod HL. Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. Pharmacogenomics 2013;14:337-9.
17. Homer N, Merriman B, Nelson SF. BFAST: an alignment tool for large scale genome resequencing. PLoS ONE 2009;4:e7767.
18. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, et al. High warfarin sensitivity in carriers of CYP2C9-35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenomics J 2014;14: 343-9.
19. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 1998;56:377-87.
20. Mkrtchian S, Sandalova T. ERp29, an unusual redox-inactive member of the thioredoxin family. Antioxid Redox Signal 2006;8:325-37.
21. Cheng Q, Guengerich FG. High-throughput fluorescence assay of cytochrome P450 3A4. In: Phillips IR, Shephard EA, Ortiz de Montellano PR, editors. Methods in Molecular Biology: Cytochrome P450 Protocols. New Jersey: Humana Press Inc; 2013. p. 157-62.
22. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000;28:1440-8.
23. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, et al. Identification and characterization of CYP3A4-20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006;79:339-49.
24. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001;11:447-58.
25. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxelinduced neuropathy. Ann Oncol 1995;6:489-94.
26. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 2013;19:821-32.
27. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
28. Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther 2012;91:1044-52.
29. Wang D, Guo Y, Wrighton SA, CookeGE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274-86.
30. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, et al. CYP3A4 intron 6 C>T SNP (CYP3A422) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 2013;14:137-49.
31. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42: 2893-6.
32. Zhang G, Nebert DW, Chakraborty R, Jin L. Statistical power of association using the extreme discordant phenotype design. Pharmacogenet Genomics 2006;16:401-13.
33. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008;26:1135-45.
34. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 2010;42:30-5.
35. Panoutsopoulou K, Tachmazidou I, Zeggini E. In search of low-frequency and rare variants affecting complex traits. Hum Mol Genet 2013;22: R16-R21.
36. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy- induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12:210-5.
37. Apellániz-RuizM, Inglada-Pérez L, G Naranjo M, Sánchez L, Mancikova V, Currás-Freixes M, et al. High frequency and founder effect of the CYP3A4-20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J 2014 Nov 4. [Epub ahead of print].